Seeking Alpha

GSK lung-cancer treatment suffers Phase III setback

  • GlaxoSmithKline's (GSK -1.8% in London) MAGE-A3 lung-cancer immunotherapeutic failed to meet two out of three primary goals in a Phase III trial.
  • The therapy didn't significantly boost disease-free survival in non-small cell lung cancer patients vs a placebo in either the overall MAGE-A3 positive population or in MAGE-A3-positive patients who did not receive chemotherapy.
  • MAGE-A3 is a tumor-specific antigen found in cancer but not in normal cells.
  • GSK will continue the trial to assess the third primary endpoint, which is designed to identify a subset of MAGE-A3 positive patients that may benefit from the treatment. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|